Full US Food and Drug Administration approval of COVID-19 vaccines could ease vaccine hesitation

[ad_1]

COVID-19 vaccines have been released and administered without full approval from the Food and Drug Administration (FDA) — and while the drugs have been allowed under Emergency Use Authorizations (EUA), some experts are looking to full approval to encourage those who are reluctant to roll up their sleeves.

The U.S. Food and Drug Administration accepted Pfizer’s request Friday for full approval for a COVID-19 vaccine more than a year after it was developed with BioNTech, and with a variable high delta.

The Food and Drug Administration (FDA) has granted a priority review of the application, and will balance full approval of the vaccine for people 16 and older by January, although an FDA spokesperson told Fox News last week that the agency expects to complete the review “before Long time” from January delivery date. Approval of the application could pave the way for official approval of the other two vaccines, Moderna, which placed its order last month, and Johnson & Johnson.

The FDA has given a priority review of Pfizer’s app and how it could pave the way for Maderna, Johnson & Johnson. (iStock)

More than 182.7 million people in the United States (more than half of the total population) have received at least one dose of the COVID-19 vaccine, according to the Centers for Disease Control and Prevention (CDC), since the Food and Drug Administration (FDA) granted permission for use in cases of Emergency. in December. The urgent need to vaccinate more Americans comes as a delta type of coronavirus infection continues to rise across the country.

Pfizer, Moderna and Johnson & Johnson each received their own EU agreement, which mandated that companies follow a set of guidelines calling for safety data from clinical trials and information about their quality and consistency, according to ScienceMag.org.

The US Food and Drug Administration’s January targets for the Pfizer COVID-19 vaccine, full approval decision

Pharmaceutical companies Pfizer, BioNTech and Moderna have already submitted applications for full approval of their vaccines to the FDA on May 7 and June 1 to begin regulatory review. J&J is also expected to file, however, and the company faced some setbacks after the U.S. Food and Drug Administration (FDA) announced earlier this month a possible link to Guillain-Barré, a rare autoimmune neurological disorder. The agency reviewed vaccine fact sheets to show an increased risk of developing the disorder after vaccination.

Science Mag reports that the difference between EUA approval and full approval from the Food and Drug Administration (FDA) involves further review of the data over a longer period of time.

After applications are submitted, the Food and Drug Administration reviews them for completeness for the first 60 days and analyzes data on safety, efficacy and manufacturing quality before issuing full approval, according to Science Mag.

Pfizer, Biontech Seeks Full FDA Approval for COVID-19 Vaccine

Full approval from the US Food and Drug Administration will allow the vaccines to be used and marketed directly to consumers in the post-pandemic era. FDA approval likely to encourage more unvaccinated Americans to get their vaccines About a third of unvaccinated adults said they would be more likely to be vaccinated if one of the COVID-19 vaccines received FDA approval, according to a Kaiser Family Foundation (KFF) survey. ) in June.

Monica Gandhi, an infectious disease physician at the University of California, San Diego, told Science Mag Wednesday that the full approval from the Food and Drug Administration “could help attract skeptics.”

“It means something for people to get approved,” Gandhi told outlets. “It seems like the simplest and easiest thing we can do now.”

Fox News’ Kayla Rivas contributed to this report.

[ad_2]